Nazal polipe sahip kronik rinosinüzitli hastalarda LRIG1 seviyeleri

Year 2023, Volume: 48 Issue: 2, 323 - 329, 02.07.2023

Sevgi Karabulut Uzunçakmak , Abdulkadir Şahin , Ayşegül Tavacı Özçelik , Zekai Halıcı

https://doi.org/10.17826/cumj.1230714

Abstract

Amaç: Nazal polipler (NP'ler), genellikle kronik rinosinüzit (KRS) ile birlikte ortaya çıkan, iltihaplanma sonucu oluşan mukozal kökenli iyi huylu kitlelerdir. Lösin açısından zengin tekrarlar ve immünoglobulin benzeri domainler 1 (Lrig1) olarak bilinen transmembran protein, Lrig ailesinin bir üyesidir. Lrig1 sıklıkla solunum yolu ve epitel dokularında eksprese edilir ve hücre proliferasyonunda yer alan birkaç sinyal yolunu inhibe edebilir. Bu çalışmanın amacı, KRS'li hastaların NP dokularındaki Lrig1 düzeylerini belirlemekti.
Gereç ve Yöntem: Bu çalışmaya KRS ve NP'li 36 hasta ile rinoplasti yapılan 15 hasta kontrol grubu olarak dahil edildi. Tüm katılımcıların Lrig1 seviyeleri ELISA yöntemi ile ölçüldü.
Bulgular: Bu çalışma, Lrig1 seviyelerinin NP dokularında kontrol grubuna göre önemli ölçüde düşük olduğunu ortaya koydu. NP dokularının ortalama Lrig1 seviyesi 22,2 ng/ml iken, kontrol grubunun ortalama seviyesi 28,5 ng/ml idi. ROC analizi sonuçlarına göre Lrig1 seviyeleri, polip dokularını kontrol dokularından ayırt etme gücüne sahiptir (AUC=0,794). Bilgisayarlı tomografi skorlama sonuçlarına göre Lrig1 seviyeleri 4-8 arası skorlanan dokularda 16-20 arası skorlanan dokulara göre daha yüksekti. Endoskopik değerlendirmelere göre skoru 5-8 veya 9-11 olan dokuların Lrig1 seviyeleri 2-4 skoru olan dokulara göre nispeten daha düşüktü.
Sonuç: NP dokularında Lrig1 seviyesinin düşük olduğu bulundu. Bu nedenle Lrigl, NP varlığını doğrulamak için kullanılabilir. Lrig1, NP derecelendirmesinde de faydalı olabilir. NP vakalarında Lrig1 seviyelerinin arttırılması, hedeflenebilir bir tedavi yöntemi olma potansiyeline sahiptir.

Keywords

Nasal polyps, Lrig1, ELISA, Rhinosinusitis

LRIG1 levels in chronic rhinosinusitis with nasal polyps

Abstract

Purpose: Nasal polyps (NPs), usually occurring together with chronic rhinosinusitis (CRS), are benign masses of mucosal origin arising from inflammation. The transmembrane protein known as leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) is a member of the Lrig family. Lrig1 is frequently expressed in the respiratory tract and epithelial tissues and can inhibit several signaling pathways involved in cell proliferation. The aim of this study was to determine Lrig1 levels in NP tissues of patients with CRS.
Material and Methods: This study included 36 patients with CRS and NPs and 15 patients who underwent rhinoplasty as the control group. The Lrig1 levels of all participants were measured by the ELISA method.
Results: This study revealed that Lrig1 levels were significantly lower in NP tissues than in tissues of the control group. The mean level of Lrig1 of the NP tissues was 22.2 ng/ml, while the mean level of the control group was 28.5 ng/ml. According to the results of ROC analysis, Lrig1 levels have the power to distinguish polyp tissues from control tissues (AUC=0.794). Lrig1 levels were higher in tissues with scores of 4-8 than in tissues with scores of 16-20 based on the results of computed tomography scoring. According to endoscopic evaluations, Lrig1 levels of tissues with scores of 5-8 or 9-11 were relatively lower than those of tissues with scores of 2-4.
Conclusion: Lrig1 levels were found to be decreased in NP tissues. Thus, Lrig1 may be used to confirm the presence of NPs. Lrig1 may also be helpful in NP grading. Increasing the Lrig1 levels in cases of NPs has the potential to become a targetable treatment modality.

Keywords

Nasal polyps, Lrig1, ELISA, Rhinosinusitis, Nasal polyps, Lrig1, ELISA, Rhinosinusitis

References

• 1. Tat TS. Omalizumab is effective in nasal polyposis with or without asthma, a real-life study. World Allergy Organ J. 2022;15:100670.
• 2. Aldajani A, Alroqi A, Alromaih S, Aloulah MO, Alsaleh S. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review. Am J Otolaryngol. 2022;43:103615.
• 3. Benjamin MR, Stevens WW, Li N,Bose S, Grammer LC, Kern RC et al. Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting. J Allergy Clin Immunol Pract. 2019;7:1010-1016.
• 4. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJT et al. Suppression of the negative regulator lrig1 contributes to erbb2 overexpression in breast cancer. Cancer Res. 2008;68:8286-94.
• 5. Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci U S A. 2006;103:11958-963.
• 6. Jensen KB , Collins CA, Nascimento E, Tan DW, Frye M, Itami S et al. Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell. 2009;4:427-39.
• 7. Lu L, Teixeira VH, Yuan Z, Graham TA, Endesfelder D, Kolluri K et al. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. J Pathol. 2013;229:608-20.
• 8. Linke R, Pries R, Könnecke M, Bruchhage KL, Böscke R, Gebhard M et al. The MEK1/2–ERK1/2 pathway is activated in chronic rhinosinusitis with nasal polyps. Arch Immunol Ther Exp (Warsz). 2014;62:217-29.
• 9. Li W, Zhou Y. Lrig1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial–mesenchymal transition. Biosci Rep. 2019;39.
• 10. Klimek L, Koennecke M, Mullol J, Hellings P W, Wang D Y, Fokkenset W et al. A possible role of stem cells in nasal polyposis. Allergy. 2017;72:1868-73.
• 11. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL et al. The leucine-rich repeat protein lrig1 is a negative regulator of erbb family receptor tyrosine kinases. J Biol Chem. 2004;279:47050-056.
• 12. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK et al. The pan-erbb negative regulator lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 2012;149:146-58.
• 13. Holgate ST. Epithelium dysfunction in asthma. J Allergy Clin Immunol. 2007;120:1233-44; quiz 1245-46.
• 14. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. a summary for otorhinolaryngologists. Rhinology. 2012;50:1-12.
• 15. Lund VJ, Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy Group. Ann Otol Rhinol Laryngol Suppl. 1995;167:17-21.
• 16. Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993;31:183-84.
• 17. Lee J-H, Chung SW, Park I-H, Lee SH, Lee SH, Lee H-M. Expression of extracellular matrix metalloproteinase inducer in nasal polyps. Am J Rhinol Allergy. 2010;24:e127-e131.
• 18. Stevens WW, Schleimer RP, Kern RC. Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2016;4:565-72.
• 19. Billing O, Holmgren Y, Nosek D, Hedman H, Hemmingsson O. Lrig1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene. 2021;40:3707-18.
• 20. Duan C, Li CW, Zhao L, Subramaniam S, Yu XM, Li YY et al. Differential expression patterns of egf, egfr, and erbb4 in nasal polyp epithelium. Xu Y, ed. PLoS One. 2016;11:e0156949.
• 21. Koennecke M, Böscke R, Pfannerstill A-C, Reers S, Elsner M, Fell B et al. Neuronal differentiation capability of nasal polyps of chronic rhinosinusitis. Arch Immunol Ther Exp (Warsz). 2017;65:431-43.
• 22. Wong VWY, Stange DE, Page ME, Buczacki S, Wabik A, Itami S et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol. 2012;14:401-08.
• 23. Frey MR, Brent Polk D. ErbB receptors and their growth factor ligands in pediatric intestinal inflammation. Pediatr Res. 2014;75:127-32.
• 24. Amishima M, Munakata M, Nasuhara Y, Sato A, Takahashi T, Homma Y et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am J Respir Crit Care Med. 1998;157:1907-12.
• 25. Matovinovic E, Solberg O, Shusterman D. Epidermal growth factor receptor - but not histamine receptor - is upregulated in seasonal allergic rhinitis. Allergy. 2003;58:472-75.
• 26. Holgate ST. Epithelial damage and response. Clin Exp Allergy. 2000;30:37-41.
• 27. Shimizu S, Takezawa-Yasuoka K, Ogawa T, Tojima I, Kouzaki H, Shimizu T. The epidermal growth factor receptor inhibitor AG1478 inhibits eosinophilic inflammation in upper airways. Clin Immunol. 2018;188:1-6.
• 28. Liu B, Guo Z, Dong H, Daofeng T, Cai Q, Ji B et al. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2. Brain Res. 2015;1611:93-100.
• 29. Chiarella E, Lombardo N, Lobello N, Aragona T, Pelaia C, Scicchitano S et al. Nasal polyposis: insights in epithelial-mesenchymal transition and differentiation of polyp mesenchymal stem cells. Int J Mol Sci. 2020;21:6878.
• 30. Cheng K-J, Zhou M-L, Liu Y-C, Zhou S-H. Roles played by the PI3K/Akt/HIF-1α pathway and IL-17A in the chinese subtype of chronic sinusitis with nasal polyps. Lor NI, ed. Mediators Inflamm. 2022;2022:1-10.
• 31. Xie R, Yang H, Xiao Q, Mao F, Zhang S, Ye F et al. Downregulation of Lrig1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation. Oncol Rep. 2013;29:177-84.
• 32. Zhang X, Song Q, Wei C, Qu J. Lrig1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells. Cell Stress Chaperones. 2015;20:631-41.
• 33. Mao F, Holmlund C, Faraz M, Bergenheim T, Johansson M, Henriksson R et al. ME-12 * The tumor suppressor lrig1 is downregulated by hypoxia and regulates glioblastoma cell invasion. Neuro Oncol. 2014;16:v122-v122.
• 34. Shin H-W, Cho K, Kim DW, Han DH, Khalmuratova R, Kim SW et al. Hypoxia-inducible factor 1 mediates nasal polypogenesis by inducing epithelial-to-mesenchymal transition. Am J Respir Crit Care Med. 2012;185:944-54.